ERBB2 and triple-negative breast carcinoma: HER2 expression allows for the choice of anti-HER2 targeted therapy, whereas the triple negative breast cancer (TNBC) subtype is usually more aggressive, with the worst prognosis, as targeted or hormonal therapy is not available and patients are treated with standard chemotherapy or radiotherapy [6].